Atlas Trials

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

Clinical trial NCT04781634 · RECRUITING

Trial details

NCT number
NCT04781634
Sponsor
Chongqing Precision Biotech Co., Ltd
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
B-ALL
Start date
2021-03-07
Primary completion
2026-12-31
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.